Lu-177-TLX591
177Lu-TLX591 (177Lu-Rosopatamab, 177Lu-J591, 177Lu-ATL-101) is the Lutetium-177 labeled J591 [...]
Lu-177-PSMA-617 (Pluvicto™)
177Lu-PSMA-617 (177Lu-Vipivotide tetratexan) is a 177Lu labeled peptide developed [...]
Ac-225-PSMA-617
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
Lu-177-iPSMA
177Lu-iPSMA is the therapeutic analogue of 99mTc-iPSMA developed at [...]
Th-227-PSMA-TTC
227Th-PSMA-TTC (227Th-BAY2315497) is a Thorium-227 labelled PSMA-targeted full IgG antibody [...]
Lu-177-EB-PSMA-617
177Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an [...]
Lu-177-CTT-1403
177Lu-CTT1403 is the therapeutic analogue of 18F-CTT1057, a phosphoramide based [...]
I-131-RPS-001
131I-RPS-001 (131I-MIP-1095) is a small radiolabeled molecule, a glutamate-urea-lysine analogue, [...]
Lu-177-PSMA-R2
177Lu-PSMA-R2 was developed as patent protected equivalent of 177Lu-PSMA-617. This [...]
Ac-225-CONV-01-α
225Ac-CONV-01-α is an alpha-radiolabeled monoclonal antibody targeting PSMA developed [...]